The new proliferation marker, tissue polypeptide-specific antigen (TPS), representing the specific epitope M3 of tissue polypeptide antigen, and three conventional biochemical markers, CEA, were analysed in 69 patients with advanced gastrointestinal tumours. The aim of our study was to assess the clinical relevance of these markers and to determine whether their use in monitoring the course of the disease can reduce the need for senral imaging procedures. At baseline, pathologically elevated TPS levels occurred in 90% of patients. CEA was elevated in 73%, CA 19-9 in 59% and CA-195 in 68%. With a detection rate of > 90% in both advanced colorectal (n = 37) and pancreatic cancer (n = 20), and of 75% in gastric cancer (n = 12), TPS was the most sensitive marker in all three tumour types included in this analysis. Serial evaluations of TPS and other biochemical markers were available in 39 patients undergoing palliative systemic chemotherapy. Treatment with a fluorouracil-based regimen resulted in a partial response in 5127 patients with colorectal cancer, whereas 2/ 12 patients with pancreatic cancer responded to therapy with a high-dose epirubicin combination regimen. All other patients had disease stabilisation or suffered from progressive disease. When compared with the results of serial CT scanning, the TPS correlated best with the course of the disease, the positive predictive value being 75% for a partial response, 96% for stable disease and partial response combined and 100% for progressive disease. The corresponding values for CEA were 50%, 81% and 62% and were similar to those for . In summary, TPS seems to represent a sensitive, clinically relevant and specific marker of proliferative activity in gastrointestinal cancer. According to our preliminary results in colorectal and pancreatic cancer, TPS may be considered as the primary means of monitoring treatment, and imaging reduced to confirm the response.
Gastrointestinal (GI) tumours are the most common type of potentially fatal malignancies in the world, and affect approximately 10,000 patients a year in Austria (Friedl, 1990) . Since there is no effective screening modality or chemoprevention, most patients present in the advanced stages when the tumour is beyond surgical cure. Conventional chemotherapy has shown only modest activity in advanced GI tumours. Although recent advances might have improved the situation in colorectal cancer (Nordic Gastrointestinal Tumor Adjuvant Therapy Group, 1992; Scheithauer et al., 1993) , clinical trials with new drugs and regimens are certainly warranted. An important issue in the chemotherapeutic management of these patients with both conventional treatment regimens and new drugs remains the early identification of non-responders, who may be spared further treatment with associated toxicity. It may also be important in some cases to evaluate the maximal response, which may allow treatment discontinuation. The response to systemic chemotherapy is usually assessed by serial imaging, commonly in the form of CT scanning. Evaluation by this means is, however, expensive and time-consuming for the patient. A simple and inexpensive method to monitor response would be the repeated measurement of tumour markers such as carcinoembyronic antigen (CEA), CA 19-9 or , which are commonly elevated in patients with gastrointestinal cancer (Martin et al., 1976; Safi et al., 1978; Kornek et al., 1992; Ward et al., 1993) . It is recognised, however, that these markers do not always accurately reflect the course of the disease. The limitations to their use in isolation is the overestimation of the number of patients who respond to treatment and, more seriously, underestimation of the number suffering progressive disease as demonstrated on CT (Allen-Mersh et al., 1986; Ward et al., 1993) .
A potentially attractive alternative to conventional tumour markers may be recently defined markers indicating tumour proliferation (Bj6rklund and Bj6rklund, 1983; Bjorklund et al., 1987) . Since dividing cells are generally more vulnerable to cytotoxic chemicals or radiation than resting ones, estimates of the tumours' proliferative activity may not only help to reduce the need for serial imaging, but may also be important with respect to the scheduling of anti-cancer therapy. During the late S and G2-phases of the cell cycle a substance termed tissue polypeptide antigen (TPA) is synthesised and released immediately into the body fluids. The concentration of the antigen in the serum seems to be a relevant indicator of the proliferative activity of cancer cells as assessed in previous clinical investigations (Gitsch et al., 1992; Van Dalen, 1992 Measurement of biochemical markers A 10 ml sample of venous blood was obtained from all patients after overnight fasting at baseline, and also in 39 patients undergoing systemic chemotherapy at monthly intervals thereafter for tumour and proliferation marker assessments. The plasma was immediately separated, and frozen at -20°C until assayed. All samples were coded and analysed independently of clinical information about the subjects.
TPS was measured by a solid-phase, two-site immunoradiometric assay (TPS IRMA Kit, Beki Diagnostic, Bromma, Sweden). All samples were run in duplicate. The mean coefficient of vanration between assays was 8%. Conventional tumour markers CEA, CA 19-9, and CA-195 (all obtained from Hybritech, Liege, Belgium) were measured by standard (immunoradiometnrc) procedures. The normal range for TPS was 0-80 U 1', CEA 0-5 ng ml-', CA 19-9 0-37 U 1-' and CA-195 0-0 U ml-' as indicated by the manufacturers.
Clinically relevant changes in TPS and conventional tumour marker levels were defined as a greater than 25% increase or a greater than 50% decrease in the markers on at least two occasions 1 month apart. For the purposes of the study, such an increase was considered to be positive as regards the detection of progressive disease (PD) and such a decrease considered to be positive in the assessment of a response (CR, PR) (Cohen and Holliday, 1982 (Main, 1987; Moertel et al., 1993) . According to the relationship of the marker level with tumour burden, their major applhtion lies in monitoring treatment response m patients with advanced diease (Malkin, 1987 It is clear that neither proliferation markers nor conventional tumour markers can replace the use of imaging procedures in the mnagement and assent of cancer patients. According to our results in paients with advanced colorectal and pancreatic cancer, however, TPS seems sufficintly sensitive and useful to be employed as the primary means of follow-up. In addition, TPS may be used with some confidence in patients in whom the disease is not easily evahlable, such as those with diffuse intraperitoneal metastass.
In conclusion, we would recommend that 
